• 00:00 1.
    index 1
  • 00:01 2.
    Identification and characterization of circPOLA2 in NSCLC
  • 00:01 3.
    Slide 1
  • 00:11 4.
    Identification and characterization of circPOLA2 in NSCLC
  • 03:51 5.
    Identification and characterization of circPOLA2 in NSCLC
  • 14:16 6.
    Correlation between circPOLA2 expression and clinicopathological features
  • 14:21 7.
    Identification and characterization of circPOLA2 in NSCLC
  • 16:16 8.
    Correlation between circPOLA2 expression and clinicopathological features
  • 25:47 9.
    CircPOLA2 suppressed the proliferation and aggressiveness of NSCLC cells
  • 29:31 10.
    CircPOLA2 suppressed the proliferation and aggressiveness of NSCLC cells
  • 32:23 11.
    CircPOLA2 sensitized non-small cell lung cancer cells to ferroptosis
  • 36:47 12.
    CircPOLA2 suppressed the tumorigenesis of NSCLC
  • 38:09 13.
    CircPOLA2 directly interacted with Merlin
  • 41:34 14.
    CircPOLA2 directly interacted with Merlin
  • 44:44 15.
    CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
  • 44:46 16.
    CircPOLA2 directly interacted with Merlin
  • 50:38 17.
    CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
  • 52:13 18.
    CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
  • 55:52 19.
    CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
  • 56:01 20.
    CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
  • 56:38 21.
    CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
  • 58:01 22.
    CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
  • 59:32 23.
    CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
  • 1:04:59 24.
    ** after 20241007.pptx
  • Index
  • Notes
  • Comment
  • Fullscreen
20241007 lab meeting_家銘
Duration: 1:05:20, Browse: 62, Last Updated: 2024-10-07
    • 00:00 1.
      index 1
    • 00:01 2.
      Identification and characterization of circPOLA2 in NSCLC
    • 00:01 3.
      Slide 1
    • 00:11 4.
      Identification and characterization of circPOLA2 in NSCLC
    • 03:51 5.
      Identification and characterization of circPOLA2 in NSCLC
    • 14:16 6.
      Correlation between circPOLA2 expression and clinicopathological features
    • 14:21 7.
      Identification and characterization of circPOLA2 in NSCLC
    • 16:16 8.
      Correlation between circPOLA2 expression and clinicopathological features
    • 25:47 9.
      CircPOLA2 suppressed the proliferation and aggressiveness of NSCLC cells
    • 29:31 10.
      CircPOLA2 suppressed the proliferation and aggressiveness of NSCLC cells
    • 32:23 11.
      CircPOLA2 sensitized non-small cell lung cancer cells to ferroptosis
    • 36:47 12.
      CircPOLA2 suppressed the tumorigenesis of NSCLC
    • 38:09 13.
      CircPOLA2 directly interacted with Merlin
    • 41:34 14.
      CircPOLA2 directly interacted with Merlin
    • 44:44 15.
      CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
    • 44:46 16.
      CircPOLA2 directly interacted with Merlin
    • 50:38 17.
      CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
    • 52:13 18.
      CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
    • 55:52 19.
      CircPOLA2 activated the Hippo pathway by inhibiting the phosphorylation of Merlin
    • 56:01 20.
      CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
    • 56:38 21.
      CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
    • 58:01 22.
      CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
    • 59:32 23.
      CircPOLA2 sensitized ferroptosis and inhibited tumorigenesis via Merlin
    • 1:04:59 24.
      ** after 20241007.pptx
    Location
    Folder name
    2024
    Author
    黃鈺涵
    Branch
    賴亮全教授
    Created
    2024-10-07 10:29:51
    Last Updated
    2024-10-07 10:50:01
    Duration
    1:05:20